Two Sigma Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.94M | Buy |
67,300
+61,000
| +968% | +$1.75M | ﹤0.01% | 1138 |
|
|
2025
Q1 | $211K | Sell |
6,300
-1,800
| -22% | -$60.4K | ﹤0.01% | 2116 |
|
|
2024
Q4 | $414K | Sell |
8,100
-14,300
| -64% | -$731K | ﹤0.01% | 1846 |
|
|
2024
Q3 | $1.14M | Sell |
22,400
-11,200
| -33% | -$572K | ﹤0.01% | 1355 |
|
|
2024
Q2 | $1.5M | Buy |
33,600
+1,800
| +6% | +$80.6K | ﹤0.01% | 1353 |
|
|
2024
Q1 | $1.49M | Sell |
31,800
-7,000
| -18% | -$328K | ﹤0.01% | 1374 |
|
|
2023
Q4 | $1.38M | Sell |
38,800
-46,100
| -54% | -$1.64M | ﹤0.01% | 1473 |
|
|
2023
Q3 | $2.52M | Buy |
84,900
+22,500
| +36% | +$669K | 0.01% | 1070 |
|
|
2023
Q2 | $1.12M | Buy |
62,400
+2,100
| +3% | +$37.8K | ﹤0.01% | 1488 |
|
|
2023
Q1 | $968K | Sell |
60,300
-39,100
| -39% | -$628K | ﹤0.01% | 1647 |
|
|
2022
Q4 | $1.82M | Sell |
99,400
-29,100
| -23% | -$533K | 0.01% | 1292 |
|
|
2022
Q3 | $2.52M | Sell |
128,500
-1,300
| -1% | -$25.5K | 0.01% | 1056 |
|
|
2022
Q2 | $2.42M | Sell |
129,800
-11,500
| -8% | -$214K | 0.01% | 1113 |
|
|
2022
Q1 | $3.1M | Sell |
141,300
-11,100
| -7% | -$244K | 0.01% | 1025 |
|
|
2021
Q4 | $4.33M | Buy |
152,400
+12,600
| +9% | +$358K | 0.01% | 831 |
|
|
2021
Q3 | $2.94M | Buy |
139,800
+54,800
| +64% | +$1.15M | 0.01% | 1046 |
|
|
2021
Q2 | $1.6M | Buy |
85,000
+50,700
| +148% | +$956K | ﹤0.01% | 1412 |
|
|
2021
Q1 | $524K | Buy |
34,300
+11,700
| +52% | +$179K | ﹤0.01% | 2006 |
|
|
2020
Q4 | $319K | Buy |
22,600
+10,300
| +84% | +$145K | ﹤0.01% | 2024 |
|
|
2020
Q3 | $193K | Buy |
12,300
+500
| +4% | +$7.85K | ﹤0.01% | 2163 |
|
|
2020
Q2 | $207K | Buy |
+11,800
| New | +$207K | ﹤0.01% | 2235 |
|